Evidence map›Paper›PMID 41647348›Full record

ArticleESMO real world data and digital oncology2025

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study.

E Fountzilas, S Karageorgopoulou, G Karakatsoulis, D Tryfonopoulos, K Papazisis, A Koutras, A Koumarianou, G Zafeiri, E Biziota, A Nikolaidi and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

E FountzilasDepartment of Medical Oncology, St Lukes's Clinic, Thessaloniki, Greece.
S KarageorgopoulouThird Department of Medical Oncology, IASO Clinic, Athens, Greece.
G KarakatsoulisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
D TryfonopoulosSecond Department of Internal Medicine, Agios Savvas Cancer Hospital, Athens, Greece.
K PapazisisDepartment of Medical Oncology, Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece.
A KoutrasDivision of Oncology, Department of Medicine, University Hospital of Patras, Medical School, Patras, Greece.
A KoumarianouHematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
G ZafeiriDepartment of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
E BiziotaDepartment of Medical Oncology, University General Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
A NikolaidiOncology Clinic, Mitera Hospital, Athens, Greece.
I BoukovinasMedical Oncology Unit, Bioclinic Thessaloniki, Thessaloniki, Greece.
E VranaThird Department of Clinical Oncology, Theagenio Cancer Hospital, Thessaloniki, Greece.
D MauriDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
E Aravantinou-FatorouSecond Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
E RazisThird Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
E VorriasOncology Department, German Oncology Center, Limassol, Cyprus.
Z SaridakiFirst Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
D BafaloukosFirst Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
A ChristopoulouMedical Oncology Unit, S. Andrew Hospital, Patras, Greece.
A BoutisThird Department of Clinical Oncology, Theagenio Cancer Hospital, Thessaloniki, Greece.
N TsoukalasDepartment of Oncology, 401 General Military Hospital of Athens, Athens, Greece.
S StamatopoulouOncology Unit, General Hospital of Kalamata, Kalamata, Greece.
N SpathasFourth Oncology Department and Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, Greece.
M TheochariOncology Unit, Hippokration General Hospital of Athens, Athens, Greece.
F ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, National Kapodistrian University of Athens School of Medicine, Athens, Greece.
A PsyrriSection of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
G FountzilasAristotle University of Thessaloniki, Thessaloniki, Greece.
E LallaThird Department of Clinical Oncology, Theagenio Cancer Hospital, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The study aimed to evaluate real-world effectiveness and toxicity data of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in pretreated patients with metastatic breast cancer (mBC). Patients and methods: A retrospective multicenter review of medical records of patients with mBC treated with T-DXd and/or SG at 24 Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG) was carried out. Patients with triple-negative BC (TNBC), HER2-positive, and/or hormone receptor (HR)-positive mBC who received at least one cycle of T-DXd and/or SG in any line of treatment were included. The primary endpoint was the toxicity rate of each drug. Results: From January 2020 to April 2024, 312 patients received treatment; 226 (72.4%) received T-DXd and 60 (19.2%) SG, while 26 (8.3%) patients received both agents. Adverse events (AEs) were reported in 57.1% of patients treated with T-DXd and 56.6% of patients treated with SG. The most common AEs were nausea (28.1%) and fatigue (22.5%) among patients treated with T-DXd, and fatigue (20.7%) and neutropenia (12.6%) among those treated with SG. Toxicity-related discontinuation was reported in 12 (8.8%) and 2 (3.2%) patients, respectively, who received T-DXd and SG. Interstitial lung disease was observed in 17 (6.9%) patients treated with T-DXd. The 12-month progression-free survival (PFS) rate was 69.6 [interquartile range (IQR) 61.4-79] in patients with HER2-positive and 46.5 (IQR 28.6-46.5) in patients with HER2-low mBC receiving T-DXd. In patients with TNBC receiving SG, the 12-month PFS rate was 16.2 (IQR 8.1-32.4), whereas in patients with HR-positive/HER2-negative mBC, it was 23.6 (IQR 13.8-40.3). Conclusions: Real-world data on the use of T-DXd and SG in patients with mBC provide significant clinical insights into the toxicity and effectiveness of each agent.

Indexed as

breast cancerHER2-lowinterstitial lung diseasereal-world datasacituzumab govitecantrastuzumab deruxtecan

Identifiers

PMID41647348
PMCPMC12836521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.